Treatment of flat warts with trifarotene

This retrospective study explores the off-label use of trifarotene, a topical retinoid currently approved only for acne in individuals aged 12 years and older for the treatment of verrucae planae (flat warts). Our study included patients aged 3 to 45 years, demonstrating a high safety and tolerability profile due to the minimal systemic absorption of trifarotene. The therapy allowed for the rapid resolution of warts, avoiding invasive and potentially scarring treatments, particularly crucial for pediatric patients and young adults. These findings suggest that trifarotene may provide a cosmetically favorable and effective alternative for managing flat warts, warranting further investigation.